OPEN MINDS On-Line News Mental Health & Chemical Dependency Services A lawsuit filed by third-party payers against Eli Lilly for damages related to Zyprexa (olanzapine), approved to treat schizophrenia and bipolar disorder, was granted class action status and the lawsuit made public on September 5, 2008. The plaintiffs say Lilly overcharged, hid side effects such as weight gain and diabetes, and encouraged physicians to use the medication for conditions not approved by the U.S. Food and Drug Administration (FDA). In addition, the plaintiffs claim that Lilly violated the Racketeer Influenced and Corrupt Organizations Act (RICO) through mail . . .

Want To Read More? Log In Or Become A Paid Member
Resource Available For Paid OPEN MINDS Circle Members Only
Not a paid member? Don't miss out! Sign up today and receive unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!
If you are already a paid member, log in to your account to access this resource and more. If you are a free member, you will need to upgrade to a paid membership before accessing this resource.

If you are not yet a paid member, learn more about the OPEN MINDS Circle Market Intelligence Service Membership on our website, reach out to our team at info@openminds.com, or call us at 877-350-6463.

The News

Daily coverage of the developments shaping health and human services. From policy shifts to program innovations, reports on trends-shaping mental health, addiction treatment, child and family services, autism and I/DD, disability support and long-term care, social services, corrections, juvenile justice, chronic disease management, health care systems, and more-helping leaders make timely, informed decisions.

Filter Options

  • By Market
  • By Topic
  • By Date Range
  • Sort Date By
  • Results Per Page
Clear Filters